171 related articles for article (PubMed ID: 12932201)
1. Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype.
Shiu SY; Law IC; Lau KW; Tam PC; Yip AW; Ng WT
J Pineal Res; 2003 Oct; 35(3):177-82. PubMed ID: 12932201
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of androgen-sensitive LNCaP prostate cancer growth in vivo by melatonin: association of antiproliferative action of the pineal hormone with mt1 receptor protein expression.
Xi SC; Siu SW; Fong SW; Shiu SY
Prostate; 2001 Jan; 46(1):52-61. PubMed ID: 11170132
[TBL] [Abstract][Full Text] [Related]
3. Potential involvement of mt1 receptor and attenuated sex steroid-induced calcium influx in the direct anti-proliferative action of melatonin on androgen-responsive LNCaP human prostate cancer cells.
Xi SC; Tam PC; Brown GM; Pang SF; Shiu SY
J Pineal Res; 2000 Oct; 29(3):172-83. PubMed ID: 11034115
[TBL] [Abstract][Full Text] [Related]
4. Melatonin MT1 receptor-induced transcriptional up-regulation of p27(Kip1) in prostate cancer antiproliferation is mediated via inhibition of constitutively active nuclear factor kappa B (NF-κB): potential implications on prostate cancer chemoprevention and therapy.
Shiu SY; Leung WY; Tam CW; Liu VW; Yao KM
J Pineal Res; 2013 Jan; 54(1):69-79. PubMed ID: 22856547
[TBL] [Abstract][Full Text] [Related]
5. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
Siu SW; Lau KW; Tam PC; Shiu SY
Prostate; 2002 Jul; 52(2):106-22. PubMed ID: 12111702
[TBL] [Abstract][Full Text] [Related]
6. Effects of MT1 melatonin receptor overexpression on the aromatase-suppressive effect of melatonin in MCF-7 human breast cancer cells.
González A; Martínez-Campa C; Mediavilla MD; Alonso-González C; Sánchez-Mateos S; Hill SM; Sánchez-Barceló EJ; Cos S
Oncol Rep; 2007 Apr; 17(4):947-53. PubMed ID: 17342341
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative action of melatonin on human prostate cancer LNCaP cells.
Moretti RM; Marelli MM; Maggi R; Dondi D; Motta M; Limonta P
Oncol Rep; 2000; 7(2):347-51. PubMed ID: 10671684
[TBL] [Abstract][Full Text] [Related]
8. Human melatonin MT1 receptor induction by valproic acid and its effects in combination with melatonin on MCF-7 breast cancer cell proliferation.
Jawed S; Kim B; Ottenhof T; Brown GM; Werstiuk ES; Niles LP
Eur J Pharmacol; 2007 Mar; 560(1):17-22. PubMed ID: 17303109
[TBL] [Abstract][Full Text] [Related]
9. Signaling mechanisms of melatonin in antiproliferation of hormone-refractory 22Rv1 human prostate cancer cells: implications for prostate cancer chemoprevention.
Tam CW; Mo CW; Yao KM; Shiu SY
J Pineal Res; 2007 Mar; 42(2):191-202. PubMed ID: 17286752
[TBL] [Abstract][Full Text] [Related]
10. Melatonin influences somatostatin secretion from human pancreatic δ-cells via MT1 and MT2 receptors.
Zibolka J; Mühlbauer E; Peschke E
J Pineal Res; 2015 Mar; 58(2):198-209. PubMed ID: 25585597
[TBL] [Abstract][Full Text] [Related]
11. Alternative Radioligands for Investigating the Molecular Pharmacology of Melatonin Receptors.
Legros C; Brasseur C; Delagrange P; Ducrot P; Nosjean O; Boutin JA
J Pharmacol Exp Ther; 2016 Mar; 356(3):681-92. PubMed ID: 26759496
[TBL] [Abstract][Full Text] [Related]
12. In vitro comparison of duration of action of melatonin agonists on melatonin MT1 receptor: possible link between duration of action and dissociation rate from receptor.
Nishiyama K; Hirai K
Eur J Pharmacol; 2015 Jun; 757():42-52. PubMed ID: 25797281
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of melatonin anticancer effects.
Hill SM; Frasch T; Xiang S; Yuan L; Duplessis T; Mao L
Integr Cancer Ther; 2009 Dec; 8(4):337-46. PubMed ID: 20050373
[TBL] [Abstract][Full Text] [Related]
14. Characterization and regulation of the human ML1A melatonin receptor stably expressed in Chinese hamster ovary cells.
Witt-Enderby PA; Dubocovich ML
Mol Pharmacol; 1996 Jul; 50(1):166-74. PubMed ID: 8700109
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic actions of melatonin in cancer: possible mechanisms.
Srinivasan V; Spence DW; Pandi-Perumal SR; Trakht I; Cardinali DP
Integr Cancer Ther; 2008 Sep; 7(3):189-203. PubMed ID: 18815150
[TBL] [Abstract][Full Text] [Related]
16. Neural stem cells express melatonin receptors and neurotrophic factors: colocalization of the MT1 receptor with neuronal and glial markers.
Niles LP; Armstrong KJ; Rincón Castro LM; Dao CV; Sharma R; McMillan CR; Doering LC; Kirkham DL
BMC Neurosci; 2004 Oct; 5():41. PubMed ID: 15511288
[TBL] [Abstract][Full Text] [Related]
17. The influence od melatonin receptors antagonists, luzindole and 4-phenyl-2-propionamidotetralin (4-P-PDOT), on melatonin-dependent vasopressin and adrenocorticotropic hormone (ACTH) release from the rat hypothalamo-hypophysial system. In vitro and in vivo studies.
Juszczak M; Roszczyk M; Kowalczyk E; Stempniak B
J Physiol Pharmacol; 2014 Dec; 65(6):777-84. PubMed ID: 25554981
[TBL] [Abstract][Full Text] [Related]
18. 17Beta-estradiol modulates hMT1 melatonin receptor function.
Masana MI; Soares JM; Dubocovich ML
Neuroendocrinology; 2005; 81(2):87-95. PubMed ID: 15809517
[TBL] [Abstract][Full Text] [Related]
19. Melatonin protects against cisplatin-induced ovarian damage in mice via the MT1 receptor and antioxidant activity.
Barberino RS; Menezes VG; Ribeiro AEAS; Palheta RC; Jiang X; Smitz JEJ; Matos MHT
Biol Reprod; 2017 Jun; 96(6):1244-1255. PubMed ID: 28595266
[TBL] [Abstract][Full Text] [Related]
20. Cetrorelix, a gonadotropin-releasing hormone antagonist, induces the expression of melatonin receptor 1a in the gonadotropin-releasing hormone neuronal cell line GT1-7.
Ishii H; Sato S; Yin C; Sakuma Y; Kato M
Neuroendocrinology; 2009; 90(3):251-9. PubMed ID: 19641296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
